Please upgrade your browser.
Argos Therapeutics Identifies Immune Response Marker Connected to Prolonged Overall Survival in mRCC Patients Treated With AGS-003
Updated Immune Analysis From Phase 2 Clinical Trial Presented at 2012 Markers in Cancer Meeting
The administration said this at a Stakeholders Forum on the ban of smoking tobacco in public places, organized by the Social Development Secretariat of the FCT as part of strategy to consolidate and strengthen the campaign against cigarette smoking in public place in the Territory
There has recently been published a report in the journal, "Cancer," that shows death rates for Americans dying from malignancies continue to trend downward.
Dr. David Avigan, Beth Israel Deaconess Medical Center, says "The goal of the vaccine is to see whether one can really re-educate our immune system to see cancer cells as foreign."
Data presented at the Markers in Cancer Meeting, October 11, Hollywood, Fla., demonstrates that a specific tumor-reactive cytotoxic T cell (CTL) subset (CD28+/CCR7+/CD45RA- phenotype) displaying a broad Markers of Immune Function (MIFs) profile correlates with progression-free survival (PFS) and overall survival (OS) in patients treated with AGS-003.
Teams of 3 to 5 riders are suggested, but individual riders are welcome. The registration fee for teams riding the full ten hours is a $250 donation to the Kidney Cancer Association. Individual rider registration is $25 per hour. All participants will receive âKidney Cancer Sucksâ orange T-shirts.
Seventy-six doctors in twenty-two states were contacted by the FDA because they may have purchased counterfeit Avastin from a "little-known drug wholesaler, Montana Healthcare Solutions," reported the Wall Street Journal.
Read about Argos Therapeutics Inc.'s ADAPT study and immunotherapy development, presented at our annual symposium in Chicago.
Another way to support kidney cancer research is by making a donation at http://kidneycancer.org.
To examine cancer-specific mortality in patients with nodal metastases relative to patients without nodal involvement at nephrectomy for non-metastatic renal cell carcinoma in a population-based cohort.
|NeonCRM by Neon One|